Phaseline

Companies › TWi Biotechnology

TWi Biotechnology: clinical trials, targets and expected readouts

1 active drug program in 1 registered trial: 1 Phase 2; Other; next expected readout Mar 2027.

Open in Phaseline: competitors, likelihood bands and readouts Company report

Programs

DrugTargetHighest phaseConditionsNext expected readout
AC-203 (diacerein 1% ointment)
Heat shock protein 70 (Hsp70) inducer; reduces inflammation and keratinocyte apoptosis in
–Phase 2Generalized Epidermolysis Bullosa SimplexMar 2027

Trials

Registry idDrugPhaseConditionsAreaExpected readout
NCT06073132AC-203 (diacerein 1% ointment)Phase 2Generalized Epidermolysis Bullosa SimplexOtherMar 2027

Targets

No annotated target.

Companies with the same targets

–

Companies built like this

Healx Skingenix Sensory Cloud Shanghai Huilun Pharmaceutical Dendrogenix

Pipelines of the same shape: areas, drug types, target families, stage and cash runway.

Programs group the company's trials by drug; the target and mechanism come from Open Targets and ChEMBL via Open Targets; expected readouts are Phaseline's estimate from the registry's primary completion date. Facts from the registries only; the approval likelihood, shown as a band with its track record, is in the app.